News
NEO
11.63
-2.47%
-0.30
NeoGenomics price target raised to $13 from $11 at BofA
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Champions Oncology (CSBR) and NeoGenomics (NEO)
TipRanks · 1d ago
NeoGenomics announce Natera withdrawal of appeal in patent litigation
TipRanks · 1d ago
Natera Ends Lawsuit, Clearing Path for NeoGenomics' RaDaR ST Launch
Benzinga · 1d ago
Natera Drops Appeal in Patent Dispute With NeoGenomics
Reuters · 1d ago
NEOGENOMICS ANNOUNCES THAT NATERA HAS VOLUNTARILY WITHDRAWN ITS APPEAL IN ONGOING RADAR PATENT LITIGATION
Reuters · 1d ago
NEOGENOMICS INC - DISMISSAL LEAVES RULING IN NEOGENOMICS' FAVOR
Reuters · 1d ago
Weekly Report: what happened at NEO last week (1208-1212)?
Weekly Report · 1d ago
U.S. RESEARCH ROUNDUP-Applied Materials, Coca-Cola, Glacier Bancorp
Reuters · 1d ago
NeoGenomics To Present Data Utilizing Its RaDaR 1.0 Assay For Detection Of Molecular Residual Disease At 2025 SABCS
Benzinga · 6d ago
NeoGenomics to Present New ctDNA Research from SURVIVE HERoes and CLEVER Trials at SABCS 2025
Reuters · 6d ago
NeoGenomics to Present New ctDNA Research at SABCS 2025
Barchart · 6d ago
NeoGenomics Data At ASH 2025 Shows Comprehensive Genomic Profiling Improves Diagnosis And Identifies Actionable Fusions In Myeloid Malignancies
Benzinga · 12/08 13:08
NeoGenomics Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis
Reuters · 12/08 13:05
Weekly Report: what happened at NEO last week (1201-1205)?
Weekly Report · 12/08 10:26
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025
Barchart · 12/08 07:05
Testing & Diagnostics Services Stocks Q3 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)
Barchart · 12/05 13:28
3 Overrated Stocks That Concern Us
Barchart · 12/04 04:56
Weekly Report: what happened at NEO last week (1124-1128)?
Weekly Report · 12/01 10:21
Alicia C. Olivo, EVP, GC & Business Development, reports disposal of NeoGenomics Inc. common shares
Reuters · 11/28 21:18
More
Webull provides a variety of real-time NEO stock news. You can receive the latest news about Neogenomics Inc through multiple platforms. This information may help you make smarter investment decisions.
About NEO
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.